NCT06628362Active, not recruitingPhase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Carmot Therapeutics, Inc.70 sites in 1 country447 target enrollmentStarted: November 21, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
- Carmot Therapeutics, Inc.
- Enrollment
- 447
- Locations
- 70
- Primary Endpoint
- Percent Change in Body Weight from Baseline to Week 36
Study Overview
Brief Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female, 18 to 75 years of age
- •Body mass index (BMI) ≥25.0 kg/m^2
- •Have a diagnosis of Type 2 Diabetes Mellitus (T2DM) according to the World Health Organization classification or other locally applicable standards
- •Have an HbA1c ≥7% and ≤10.5%
- •Management of T2DM with diet and exercise alone, metformin, or a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, as monotherapy or in combination, per approved local label
- •At least one self-reported unsuccessful diet/exercise effort to lose body weight
Exclusion Criteria
- •Have Type 1 Diabetes Mellitus (T1DM), history of ketosis or hyperosmolar state/coma, or any other types of diabetes except T2DM
- •Have had 1 or more episodes of Level 3 hypoglycemia or have had hypoglycemia unawareness within 3 months prior to screening
- •Have history or presence of proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment
- •Have evidence of clinically significant autonomic neuropathy (symptoms may include resting tachycardia, orthostatic hypotension, or diabetic diarrhea)
- •Had treatment with any oral antihyperglycemic medications, with the exception of metformin or SGLT-2 inhibitors, within 3 months prior to screening or planned concurrent treatment with these medications during the study
- •Had treatment with injectable antihyperglycemic medication, with the exception of short-term insulin, within 6 months prior to screening or planned concurrent treatment with these medications during the study
- •Self-reported body weight change of >5 kg within 3 months before screening
- •Any unbalanced/extreme diets, such as very low calorie, low carbohydrate, very high protein, ketogenic, or intermittent diets, within 3 months of the screening visit, or plan to be on such diets during the study
- •Current or recent use of any treatment that promotes weight loss or glucose metabolism
- •Current or recent use of treatment that may cause weight gain
- •Prior or planned surgical treatment or procedure for obesity, except for liposuction or abdominoplasty if performed >1 year prior to screening. Participants with a history of devices, such as LAP-BAND® or intragastric balloon, are permitted, if devices were removed >1 year prior to screening.
- •History of clinically significant or active gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction, intestinal obstruction), or chronic use of medications that directly affect GI motility
- •History of chronic pancreatitis or acute pancreatitis or have signs and symptoms of acute pancreatitis at screening
- •Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity
- •History or diagnosis of significant active or unstable major depressive disorder or any history/diagnosis of other severe psychiatric conditions (e.g., schizophrenia; bipolar disorder; other serious mood disorder or anxiety disorder, or hyperactivity disorder) within the last year before screening
- •History of any hematologic conditions that may interfere with HbA1c measurement (e.g., hemolytic anemias, sickle cell disease, other hemoglobinopathies)
- •Family or personal history of medullary thyroid carcinoma
- •Women who are pregnant, breastfeeding, or intend to become pregnant, or are of childbearing potential and not using a highly effective contraceptive method as required per protocol
Arms & Interventions
Arm 1: Placebo
Placebo Comparator
Intervention: Placebo (Drug)
Arm 3: Enicepatide Dose Level 2
Experimental
Intervention: Enicepatide (Drug)
Arm 4: Enicepatide Dose Level 3
Experimental
Intervention: Enicepatide (Drug)
Arm 5: Enicepatide Dose Level 4 (High)
Experimental
Intervention: Enicepatide (Drug)
Arm 2: Enicepatide Dose Level 1 (Low)
Experimental
Intervention: Enicepatide (Drug)
Outcomes
Primary Outcomes
Percent Change in Body Weight from Baseline to Week 36
Time Frame: Baseline to Week 36
Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36
Time Frame: Baseline to Week 36
Secondary Outcomes
- Percent Change in Body Weight from Baseline to Week 48(Baseline to Week 48)
- Change in HbA1c from Baseline to Week 48(Baseline to Week 48)
- Percentage of Participants with HbA1c <7.0% at Weeks 36 and 48(Weeks 36 and 48)
- Percentage of Participants with Body Weight Reduction ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from Baseline to Week 36(Baseline and Week 36)
- Percentage of Participants with Body Weight Reduction ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from Baseline to Week 48(Baseline and Week 48)
- Percent Change in Body Weight from Baseline to Week 28(Baseline and Week 28)
- Absolute Change in Body Weight (kg) from Baseline to Weeks 36 and 48(Baseline to Weeks 36 and 48)
- Percent Change in Body Weight from Baseline to Weeks 16, 28, 36, and 48 by Obesity Class(Baseline to Weeks 16, 28, 36, and 48)
- Change in HbA1c from Baseline to Weeks 16 and 28(Baseline to Weeks 16 and 28)
- Change in HbA1c from Baseline to Weeks 16, 28, 36, and 48 by Obesity Class(Baseline to Weeks 16, 28, 36, and 48)
- Percentage of Participants with HbA1c ≤6.5% at Weeks 16, 28, 36, and 48(Weeks 16, 28, 36, and 48)
- Percentage of Participants with HbA1c <5.7% at Weeks 16, 28, 36, and 48(Weeks 16, 28, 36, and 48)
- Change in 7-point Self-Monitored Blood Glucose (SMBG) Profile at Weeks 16, 28, 36, and 48(Weeks 16, 28, 36, and 48)
- Percentage of Participants who Achieve HbA1c ≤6.5% and ≥10.0% Weight Reduction at Weeks 16, 28, 36, and 48(Baseline, Weeks 16, 28, 36, and 48)
- Percentage of Participants who Achieve HbA1c <7.0% and ≥5.0% Weight Reduction at Weeks 16, 28, 36, and 48(Baseline, Weeks 16, 28, 36, and 48)
- Change in Body Mass Index (BMI) from Baseline to Weeks 36 and 48(Baseline, Weeks 36 and 48)
- Change in Waist Circumference from Baseline to Weeks 36 and 48(Baseline, Weeks 36 and 48)
- Change in Hip Circumference from Baseline to Weeks 36 and 48(Baseline, Weeks 36 and 48)
- Change in Waist-to-Hip Ratio from Baseline to Weeks 36 and 48(Baseline, Weeks 36 and 48)
- Change in Waist-to-Height Ratio from Baseline to Weeks 36 and 48(Baseline, Weeks 36 and 48)
- Change in Fasting Plasma Glucose from Baseline to Weeks 16, 28, 36, and 48(Baseline to Weeks 16, 28, 36, and 48)
- Change in Fasting Insulin from Baseline to Weeks 16, 28, 36, and 48(Baseline to Weeks 16, 28, 36, and 48)
- Change in Fasting C-peptide from Baseline to Weeks 16, 28, 36, and 48(Baseline to Weeks 16, 28, 36, and 48)
- Change in Fasting Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) from Baseline to Weeks 16, 28, 36, and 48(Baseline to Weeks 16, 28, 36, and 48)
Investigators
Study Sites (70)
Loading locations...
Similar Trials
Completed
Phase 2
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityOverweightObesityNCT06525935Carmot Therapeutics, Inc.469
Completed
Phase 2
Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)Atrial FibrillationNCT03906799Omeicos Therapeutics GmbH136
Completed
Phase 2
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic AsthmaEosinophilic AsthmaAsthmaNCT04046939Knopp Biosciences534
Completed
Phase 3
Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle SprainAcute Ankle SprainNCT01874626Strategic Science & Technologies, LLC305
Completed
Phase 3
Lumateperone for the Prevention of Relapse in Patients With SchizophreniaSchizophreniaNCT04959032Intra-Cellular Therapies, Inc.228
Related News
Roche's Enicepatide Hits Both Phase II Endpoints in Type 2 Diabetes, With 2.65% HbA1c Drop at 24 mg- Roche reported that once-weekly enicepatide met both primary endpoints in the Phase II CT-388-104 trial, producing dose-dependent reductions in HbA1c and body weight at 48 weeks.
- At the highest titrated 24 mg dose, patients achieved a mean HbA1c reduction of 2.65% and mean weight loss of 15.5% without a demonstrable plateau.
- Ninety percent of patients in the 24 mg arm reached the type 2 diabetes glycemic threshold of HbA1c 6.5% or below, and 62% achieved normoglycemia.
- Treatment discontinuation due to adverse events was 2.0% in enicepatide arms versus 0.0% on placebo, with mostly mild-to-moderate gastrointestinal events.21 hours agoGenentech's dual GLP-1/GIP agonist enicepatide cuts HbA1c 2.65% and weight 15.5% at 48 weeks in Phase II T2D trial- Genentech reported positive topline Phase II results for enicepatide, a once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes and overweight or obesity.
- At the 24 mg dose, enicepatide reduced HbA1c by 2.65% and body weight by 15.5% at 48 weeks, meeting both dual primary endpoints.
- Ninety percent of patients on 24 mg reached HbA1c of 6.5% or below and 62% achieved normoglycemia, while patients with baseline HbA1c above 8.5% saw a 4.13% reduction.
- Treatment discontinuation due to adverse events was 2.0% in enicepatide arms versus 0.0% on placebo, with mostly mild-to-moderate gastrointestinal events.23 hours ago